UBS AM
AEGR

UBS AM’s Aegerion Pharmaceuticals AEGR Stock Holding History

UBS AM’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-19,800
Closed -$73K – 2652
2016
Q1 		$73K Sell
19,800
-2,277
-10% -$14.1K ﹤0.01% 2597
2015
Q4 		$223K Sell
22,077
-3,500
-14% -$42.1K ﹤0.01% 2477
2015
Q3 		$348K Buy
25,577
+9,800
+62% +$174K ﹤0.01% 2212
2015
Q2 		$299K Sell
15,777
-361,600
-96% -$7.83M ﹤0.01% 2366
2015
Q1 		$9.88M Buy
377,377
+500
+0.1% +$12.7K 0.01% 886
2014
Q4 		$7.89M Sell
376,877
-72,700
-16% -$1.83M 0.01% 932
2014
Q3 		$15M Buy
449,577
+20,214
+5% +$627K 0.01% 747
2014
Q2 		$13.8M Buy
429,363
+51,786
+14% +$1.93M 0.01% 768
2014
Q1 		$17.4M Buy
377,577
+249,400
+195% +$14.6M 0.02% 702
2013
Q4 		$9.1M Sell
128,177
-5,300
-4% -$405K 0.01% 846
2013
Q3 		$11.4M Sell
133,477
-127,676
-49% -$10.8M 0.01% 775
2013
Q2 		$16.5M Buy
+261,153
New +$13.9M 0.02% 626

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM's AEGR Position: Q2 2016 in Review

UBS AM sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 19,800 shares — an estimated $73K sold.

UBS AM first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $17.4M in Q1 2014. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • UBS AM reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • UBS AM sold 19,800 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $73K.
  • UBS AM first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • UBS AM's Aegerion Pharmaceuticals position peaked at $17.4M in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on UBS AM's 13F filing for Q2 2016, filed 9 Aug 2016.